Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. [cited 2024 Jul 28];74(3):229–63. Available from: https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.3322/caac.21834

Chiappa C, Greta M, Miriam L, Ietto G, Inversini D, Ballabio A et al (2024) Neoadjuvant chemotherapy in breast cancer: evaluation of the impact on surgical outcomes and prognosis. Cancers (Basel) [Internet]. [cited 2024 Jul 28];16(13). Available from: /pmc/articles/PMC11240326/

Jankowski C, Michel E, Vincent L, Beltjens F, Arnould L, Ladoire S et al (2023) Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact. Bull Cancer 110(6):605–615

Article  PubMed  Google Scholar 

Boileau JF, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study. J Clin Oncol [Internet]. [cited 2024 Aug 31];33(3):258–63. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/JCO.2014.55.7827

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol [Internet]. [cited 2024 Aug 31];14(7):609–18. Available from: http://www.thelancet.com/article/S1470204513701669/fulltext

Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF et al (2019) Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat [Internet]. [cited 2024 Jul 28];173(2):343–52. Available from: https://link.springer.com/article/https://doi.org/10.1007/s10549-018-5004-7

McVeigh TP, Al-Azawi D, Kearney DE, Malone C, Sweeney KJ, Barry K et al (2014) Assessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancer. Clin Breast Cancer 14(1):20–25

Article  PubMed  Google Scholar 

Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF et al (2016) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. [Internet]. [cited 2024 Jul 28];23(25):5983–92. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/JCO.2005.06.232

Morgan C, Stringfellow TD, Rolph R, Kovacs T, Kothari A, Pinder SE et al (2020) Neoadjuvant chemotherapy in patients with breast cancer: does response in the breast predict axillary node response? Eur J Surg Oncol 46(4):522–526

Article  PubMed  CAS  Google Scholar 

Batt J, Chambers A, Al-Allak A, Vestey S, Hunt R, Massey E et al (2020) Neo-Adjuvant chemotherapy and its affects to the axilla—can we safely downgrade axillary surgery to mirror the approach in the breast. Breast J [Internet]. [cited 2024 Jul 28];26(9):1667–72. Available from: https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1111/tbj.13945

Zetterlund LH, Frisell J, Zouzos A, Axelsson R, Hatschek T, de Boniface J et al (2017) Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer. Breast Cancer Res Treat [Internet]. [cited 2024 Jul 28];163(1):103–10. Available from: https://link.springer.com/article/https://doi.org/10.1007/s10549-017-4164-1

Hong J, Tong Y, He J, Chen X, Shen K (2021) Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery. Ther Adv Med Oncol [Internet]. [cited 2024 Jul 28];13. Available from: https://journals.sagepub.com/doi/full/https://doi.org/10.1177/1758835921996673

Grašič Kuhar C, Geiger J, Schwab FD, Heinzelmann-Schwartz V, Vetter M, Weber WP et al (2024) Prognostic importance of axillary lymph node response to neoadjuvant systemic therapy on axillary surgery in breast cancer—a single center experience. Cancers (Basel) [Internet]. [cited 2024 Jul 28];16(7). Available from: /pmc/articles/PMC11010874/

Noronha J, Joshi S, Hawaldar R, Nair N, Vanmali V, Parmar V et al (2020) Sterilization rate of the axilla after neoadjuvant chemotherapy: the scope for conservative surgery. JCO Glob Oncol [Internet]. [cited 2024 Jul 28];(6):1184–91. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/GO.20.00195

Ryu JM, Choi HJ, Park EH, Kim JY, Lee YJ, Park S et al (2022) Relationship between breast and axillary pathologic complete response according to clinical nodal stage: a nationwide study from Korean Breast Cancer Society. J Breast Cancer [Internet]. [cited 2024 Jul 28];25(2):94. Available from: /pmc/articles/PMC9065358/

Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg [Internet]. [cited 2024 Jul 28];156(6):e210891–e210891. Available from: https://jamanetwork.com/journals/jamasurgery/fullarticle/2778930

Chen SC, Yu CC, Chang HK, Lin YC, Lo YF, Shen SC et al (2021) Discrepancy of breast and axillary pathologic complete response and outcomes in different subtypes of node-positive breast cancer after neoadjuvant chemotherapy. J Cancer [Internet]. [cited 2024 Jul 28];12(17):5365. Available from: /pmc/articles/PMC8317533/

Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu J et al (2019) Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat [Internet]. [cited 2024 Jul 28];176(3):591–6. Available from: https://link.springer.com/article/https://doi.org/10.1007/s10549-019-05214-y

Choudhary P, Gogia A, Deo SVS, Sharma D, Mathur S, Batra A et al (2021) Correlation of pathological complete response with outcomes in locally advanced breast cancer treated with neoadjuvant chemotherapy: an ambispective study. Cancer Res Stat Treat [Internet]. [cited 2024 Jul 28];4(4):611. Available from: https://journals.lww.com/crst/fulltext/2021/10000/correlation_of_pathological_complete_response_with.3.aspx

Cerbelli B, Botticelli A, Pisano A, Campagna D, De Vincentiis L, Pernazza A et al (2019) Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: are we ready to endorse axillary conservation?. Breast J [Internet]. [cited 2024 Jul 28];25(2):273–7. Available from: https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1111/tbj.13206

Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M et al (2016) How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol [Internet]. [cited 2024 Jul 28];23(11):3467–74. Available from: https://link.springer.com/article/https://doi.org/10.1245/s10434-016-5246-8

Joshi S, Chougle Q, Noronha J, Hawaldar R, Nair N, Vanmali V et al (2024) Determinants of pathological complete response to neoadjuvant chemotherapy in breast cancer: a single-institution experience. Indian J Cancer [Internet]. [cited 2024 Oct 2];61(2):324–31. Available from: https://journals.lww.com/indianjcancer/fulltext/2024/61020/determinants_of_pathological_complete_response_to.18.aspx

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol [Internet]. [cited 2024 Jul 28];13(1):25–32. Available from: http://www.thelancet.com/article/S1470204511703369/fulltext

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278–2284

Article  PubMed  CAS  Google Scholar 

Wang Y, Li L, Liu X, Wang Y, Tang Z, Wu Y et al (2021) Treatment response correlation between primary tumor and axillary lymph nodes after neoadjuvant therapy in breast cancer: a retrospective study based on real-world data. Gland Surg [Internet]. [cited 2024 Jul 28];10(2):656. Available from: /pmc/articles/PMC7944072/

Zhu J, Li J, Fan Z, Wang H, Zhang J, Yin Y et al (2020) Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy. Ann Transl Med [Internet]. [cited 2024 Jul 28];8(16):992–992. Available from: /pmc/articles/PMC7475504/

Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC (2018) Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg [Internet]. [cited 2024 Jul 28];153(12):1120–6. Available from: https://jamanetwork.com/journals/jamasurgery/fullarticle/2698682

Cipolla C, Lupo S, Grassi N, Battaglia MC, Mesi C, Scandurra G et al (2024) The impact of neoadjuvant chemotherapy on axillary surgical management of patients with breast cancer and positive axillary lymph nodes. Anticancer Res [Internet]. [cited 2024 Jul 28];44(5):2047–53. Available from: https://ar.iiarjournals.org/content/44/5/2047

Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM et al (2024) Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol [Internet]. [cited 2024 Jul 28];10(6):793–8. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2817953

Citgez B, Yigit B, Yetkin SG (2021) Management of the axilla and the breast after neoadjuvant chemotherapy in patients with breast cancer: a systematic review. Med Bull Sisli Etfal Hospital [Internet]. [cited 2024 Jul 28];55(2):156. Available from: /pmc/articles/PMC8298068/

Song YX, Xu Z, Liang MX, Liu Z, Hou JC, Chen X et al (2022) Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis. Cancer Med [Internet]. [cited 2024 Jul 28];11(22):4085–103. Available from: https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1002/cam4.4769

Krivorotko P, Emelyanov A, Komyahov A, Zhiltsova E, Gigolaeva L, Tabagua T et al (2022) Axillary surgery after neoadjuvant chemotherapy in breast cancer patients downstaging from cN+ to ycN0. [Internet]. [cited 2024 Jul 28];40(16_suppl):e12580–e12580. Available from: https://ascopubs.org/doi/https://doi.org/10.1200/JCO.2022.40.16_suppl.e12580

Pfob A, Kokh DB, Surovtsova I, Riedel F, Morakis P, Heil J (2024) Oncologic outcomes for different axillary staging techniques in patients with nodal-positive breast cancer undergoing neoadjuvant systematic treatment: a cancer registry study. Ann Surg Oncol [Internet]. [cited 2024 Jul 28];31(7):4381–92. Available from: https://link.springer.com/article/https://doi.org/10.1245/s10434-024-15292-y